Dosing of incretin pathway drugs
AssigneeClosed Loop Medicine Ltd.
InventorsPaul Goldsmith, David Bruce Campbell, Michael Catt, Tom Godec, Joe Coghlin
Life of this patent
Estimating the term…
Abstract
A method for administering a dosage of Cagrisema to a patient for the treatment of obesity, the method comprising: administering a dosage of Cagrisema to the patient, wherein the dosage of Cagrisema is determined by: receiving patient data relating to a patient, wherein the patient data includes patient weight data; and processing the patient data including the patient weight data with a dosage calculator to determine the dosage of Cagrisema for administering to the patient wherein the dosage calculator is derived from a pharmacokinetic, PK, model.
Claims24
A method for administering a dosage of Cagrisema to a patient for the treatment of obesity, the method comprising:
- administering a dosage of Cagrisema to the patient, wherein the dosage of Cagrisema is determined by:
- receiving patient data relating to a patient, wherein the patient data includes patient weight data;
- and
- processing a target end point and the patient data including the patient weight data with a dosage calculator to calculate the dosage of Cagrisema for administering to the patient wherein the dosage calculator is derived from a pharmacokinetic, PK, model comprising a time-based differential equation model for modelling a dependence of a Cagrisema concentration in the patient as a function of patient data and dosage of Cagrisema,
- wherein the target end point comprises one or more of:
- a target weight loss;
- or
- a target side effect level.
A method for treating a patient for obesity, the method comprising:
- receiving patient data relating to the patient, wherein the patient data includes patient weight data;
- processing a target end point and the patient data including the patient weight data with a dosage calculator to calculate an effective dosage of Cagrisema to administer to the patient, wherein the dosage calculator is derived from a pharmacokinetic, PK, model comprising a time-based differential equation model for modelling a dependence of a Cagrisema concentration in the patient as a function of patient data and dosage of Cagrisema, wherein the target end point comprises one or more of:
- a target weight loss;
- or
- a target side effect level;
- and
- administering the calculated effective dosage of Cagrisema to the patient to treat the patient for obesity.
Dependencies are inferred from the claim text.